New insights in the transcriptional activity and coregulator molecules in the arterial wall

Filomena De Nigris, Lilach O. Lerman, Claudio Napoli

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

A number of vascular diseases are associated with abnormal expression of genes that contribute to their pathophysiological and clinical manifestations, but at the same time offer potential therapeutic targets. One of the promising therapeutic approaches targets the pathophysiological pathways leading to aberrant gene activation, namely transcriptional activity and its molecular modulators (agonists, antagonists, coregulators, and nuclear receptors). The transcription factors can be divided into four classes (I-IV) classified by structural elements, like basic leucine zipper (bZIP) or basic helix-loop-helix (bHLH), which mediate their DNA binding activity but also determine the classes of drugs that can affect their activity. For example, statins modulate activation of the class-I transcription factor sterol responsive element-binding protein (SREBP), whose target genes including hydroxyl-methyl-glutaryl acetyl Coenzyme-A (HMG-CoA) reductase, HMG-CoA synthase, and the low-density lipoprotein receptor, all of which are involved in cholesterol and fatty acid metabolism. Similarly, insulin-like drugs target the nuclear receptor peroxisome-proliferator-activator-receptor (PPAR)-γ (class-II), several anti-inflammatory drugs inhibit activation of nuclear factor kappa B (NFκB) (class-IV), while others (e.g. flavopiridol, rapamycin, and paclitaxel) target regulation of cell-cycle proteins. Increased understanding of the genetic and molecular basis of disease (e.g. transcriptional activity and its coregulation) will potentially enhance future diagnosis, treatment, and prevention of vascular diseases.

Original languageEnglish
Pages (from-to)153-168
Number of pages16
JournalInternational Journal of Cardiology
Volume86
Issue number2-3
DOIs
Publication statusPublished - Dec 2002

Fingerprint

Acetyl Coenzyme A
alvocidib
Cytoplasmic and Nuclear Receptors
Vascular Diseases
Hydroxyl Radical
Transcription Factors
Peroxisome Proliferators
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Leucine Zippers
Cell Cycle Proteins
NF-kappa B
LDL Receptors
Sterols
Sirolimus
Paclitaxel
Pharmaceutical Preparations
Transcriptional Activation
Molecular Biology
Carrier Proteins
Oxidoreductases

Keywords

  • Cardiovascular disease
  • Drugs
  • Nuclear factor kappa B
  • Peroxisome proliferator activator receptor
  • Sterol responsive element-binding protein
  • Transcription factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

New insights in the transcriptional activity and coregulator molecules in the arterial wall. / De Nigris, Filomena; Lerman, Lilach O.; Napoli, Claudio.

In: International Journal of Cardiology, Vol. 86, No. 2-3, 12.2002, p. 153-168.

Research output: Contribution to journalArticle

@article{e7a9e6b8eaf44f21a93797f04ffde1a3,
title = "New insights in the transcriptional activity and coregulator molecules in the arterial wall",
abstract = "A number of vascular diseases are associated with abnormal expression of genes that contribute to their pathophysiological and clinical manifestations, but at the same time offer potential therapeutic targets. One of the promising therapeutic approaches targets the pathophysiological pathways leading to aberrant gene activation, namely transcriptional activity and its molecular modulators (agonists, antagonists, coregulators, and nuclear receptors). The transcription factors can be divided into four classes (I-IV) classified by structural elements, like basic leucine zipper (bZIP) or basic helix-loop-helix (bHLH), which mediate their DNA binding activity but also determine the classes of drugs that can affect their activity. For example, statins modulate activation of the class-I transcription factor sterol responsive element-binding protein (SREBP), whose target genes including hydroxyl-methyl-glutaryl acetyl Coenzyme-A (HMG-CoA) reductase, HMG-CoA synthase, and the low-density lipoprotein receptor, all of which are involved in cholesterol and fatty acid metabolism. Similarly, insulin-like drugs target the nuclear receptor peroxisome-proliferator-activator-receptor (PPAR)-γ (class-II), several anti-inflammatory drugs inhibit activation of nuclear factor kappa B (NFκB) (class-IV), while others (e.g. flavopiridol, rapamycin, and paclitaxel) target regulation of cell-cycle proteins. Increased understanding of the genetic and molecular basis of disease (e.g. transcriptional activity and its coregulation) will potentially enhance future diagnosis, treatment, and prevention of vascular diseases.",
keywords = "Cardiovascular disease, Drugs, Nuclear factor kappa B, Peroxisome proliferator activator receptor, Sterol responsive element-binding protein, Transcription factors",
author = "{De Nigris}, Filomena and Lerman, {Lilach O.} and Claudio Napoli",
year = "2002",
month = "12",
doi = "10.1016/S0167-5273(02)00328-5",
language = "English",
volume = "86",
pages = "153--168",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - New insights in the transcriptional activity and coregulator molecules in the arterial wall

AU - De Nigris, Filomena

AU - Lerman, Lilach O.

AU - Napoli, Claudio

PY - 2002/12

Y1 - 2002/12

N2 - A number of vascular diseases are associated with abnormal expression of genes that contribute to their pathophysiological and clinical manifestations, but at the same time offer potential therapeutic targets. One of the promising therapeutic approaches targets the pathophysiological pathways leading to aberrant gene activation, namely transcriptional activity and its molecular modulators (agonists, antagonists, coregulators, and nuclear receptors). The transcription factors can be divided into four classes (I-IV) classified by structural elements, like basic leucine zipper (bZIP) or basic helix-loop-helix (bHLH), which mediate their DNA binding activity but also determine the classes of drugs that can affect their activity. For example, statins modulate activation of the class-I transcription factor sterol responsive element-binding protein (SREBP), whose target genes including hydroxyl-methyl-glutaryl acetyl Coenzyme-A (HMG-CoA) reductase, HMG-CoA synthase, and the low-density lipoprotein receptor, all of which are involved in cholesterol and fatty acid metabolism. Similarly, insulin-like drugs target the nuclear receptor peroxisome-proliferator-activator-receptor (PPAR)-γ (class-II), several anti-inflammatory drugs inhibit activation of nuclear factor kappa B (NFκB) (class-IV), while others (e.g. flavopiridol, rapamycin, and paclitaxel) target regulation of cell-cycle proteins. Increased understanding of the genetic and molecular basis of disease (e.g. transcriptional activity and its coregulation) will potentially enhance future diagnosis, treatment, and prevention of vascular diseases.

AB - A number of vascular diseases are associated with abnormal expression of genes that contribute to their pathophysiological and clinical manifestations, but at the same time offer potential therapeutic targets. One of the promising therapeutic approaches targets the pathophysiological pathways leading to aberrant gene activation, namely transcriptional activity and its molecular modulators (agonists, antagonists, coregulators, and nuclear receptors). The transcription factors can be divided into four classes (I-IV) classified by structural elements, like basic leucine zipper (bZIP) or basic helix-loop-helix (bHLH), which mediate their DNA binding activity but also determine the classes of drugs that can affect their activity. For example, statins modulate activation of the class-I transcription factor sterol responsive element-binding protein (SREBP), whose target genes including hydroxyl-methyl-glutaryl acetyl Coenzyme-A (HMG-CoA) reductase, HMG-CoA synthase, and the low-density lipoprotein receptor, all of which are involved in cholesterol and fatty acid metabolism. Similarly, insulin-like drugs target the nuclear receptor peroxisome-proliferator-activator-receptor (PPAR)-γ (class-II), several anti-inflammatory drugs inhibit activation of nuclear factor kappa B (NFκB) (class-IV), while others (e.g. flavopiridol, rapamycin, and paclitaxel) target regulation of cell-cycle proteins. Increased understanding of the genetic and molecular basis of disease (e.g. transcriptional activity and its coregulation) will potentially enhance future diagnosis, treatment, and prevention of vascular diseases.

KW - Cardiovascular disease

KW - Drugs

KW - Nuclear factor kappa B

KW - Peroxisome proliferator activator receptor

KW - Sterol responsive element-binding protein

KW - Transcription factors

UR - http://www.scopus.com/inward/record.url?scp=0036888708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036888708&partnerID=8YFLogxK

U2 - 10.1016/S0167-5273(02)00328-5

DO - 10.1016/S0167-5273(02)00328-5

M3 - Article

VL - 86

SP - 153

EP - 168

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2-3

ER -